Comparing Early Enteral Nutrition Versus Parenteral Nutrition After Pancreaticoduodenectomy
NCT ID: NCT04704895
Last Updated: 2021-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
210 participants
INTERVENTIONAL
2021-02-01
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Oral Feeding for Patients After Pancreaticoduodenectomy
NCT05573399
Early Oral Intake After Pancreaticoduodenectomy in the Age of ERAS
NCT02941484
Enteral vs. Oral Nutrition After Pancreatoduodenectomy
NCT05042882
Postoperative Artificial Nutrition After Pancreaticoduodenectomy
NCT01580527
Early Enteral Nutrition in Severe Acute Pancreatitis
NCT02000323
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Arm B: NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 h or more.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Total parenteral nutrition
Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
Total parenteral nutrition
Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
Arm B: Enteral nutrition
NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
Enteral nutrition
NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Total parenteral nutrition
Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
Enteral nutrition
NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients underwent pancreaticoduodenectomy;
* ECOG 0 \~ 2 for physical condition score;
* Imaging examination found pancreatic head, periampullary space, no distant metastasis and ascites;
* No bone marrow dysfunction;
* Those without obvious surgical contraindications;
* Expected postoperative survival ≥3 months;
* The study visit plan and other programme requirements are now available;
* Voluntary participation and signing of informed consent.
Exclusion Criteria
* Active infected persons;
* Distant metastasis or ascites were found in imaging examination;
* Patients with serious impairment of heart, liver and kidney function (grade 3 to 4, ALT and/or AST more than 3 times the normal upper limit, Cr more than the normal upper limit);
* patients with other malignant tumors or blood diseases;
* Pregnancy, planned pregnancy and lactation female patients (urine HCG \>02500 iu /L, diagnosed as early pregnancy);
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xian-Jun Yu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xian-Jun Yu
President of Pancreatic Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
Shanghai, Sahnghai, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xianjun Yu, Phd
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSPAC-32
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.